LLY
ELI LILLY & Co
NYSE: LLY · Indianapolis, IN · Healthcare
$1144.68-4.47 (-0.39%)Closed
Market Cap$1077.22B
Cash$5.28Bmost recent
Runwayprofitable
P/E (TTM)49.8EPS $22.95
52-Wk Range$621.26 – $1149.15
Avg Volume3.6M3-month
Price & Trading Activity
Daily close with catalyst overlays and trading volume
$1144.68+34.2%
Pipeline
Drug candidates sponsored by ELI LILLY & · ClinicalTrials.gov
| Phase | Drug / Candidate | Indications | Status | Next Completion | Trials | |
|---|---|---|---|---|---|---|
| Phase 4 | olanzapine | Bipolar Disorder+1 more | Completed | 2009-05past | 3 | |
| Phase 4 | Duloxetine hydrochloride | Major Depressive Disorder+1 more | Completed | 2009-07past | 2 | |
| Phase 4 | Insulin lispro | Diabetes Mellitus, Type 2 | Completed | 2013-01past | 1 | |
| Phase 4 | Ixekizumab | Plaque Psoriasis+5 more | Completed | 2024-08-08past | 5 | |
| Phase 4 | Baricitinib | Rheumatoid Arthritis+1 more | Completed | 2025-05-19past | 2 | |
| Phase 4 | Atomoxetine | Attention-Deficit/Hyperactivity Disorder+1 more | Completed | — | 1 | |
| Phase 4 | tadalafil | Impotence+2 more | Completed | — | 4 | |
| Phase 3 | simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder | Diabetes Mellitus, Type 2 | Completed | 2008-05past | 1 | |
| Phase 3 | Duloxetine hydrochloride - 40 mg | Diabetic Neuropathies | Completed | 2009-03past | 1 | |
| Phase 3 | Teriparatide | Osteoporosis | Completed | 2010-12past | 3 | |
| Phase 3 | Tasisulam-sodium | Melanoma | Terminated | 2011-03past | 1 | |
| Phase 3 | pemetrexed | Non Small Cell Lung Carcinoma+15 more | Completed | 2012-11past | 7 | |
| Phase 3 | LY2127399 | Systemic Lupus Erythematosus+3 more | Completed | 2014-08past | 2 | |
| Phase 3 | Dulaglutide | Type 2 Diabetes+3 more | Completed | 2016-06past | 2 | |
| Phase 3 | Ramucirumab | Colorectal Cancer+6 more | Completed | 2017-10-25past | 5 | |
| Phase 3 | LY900014 | Type 1 Diabetes Mellitus+2 more | Completed | 2022-01-10past | 3 | |
| Phase 3 | Selpercatinib | Non-Small Cell Lung Cancer+4 more | Active, not recruiting | 2023-05-01past | 3 | |
| Phase 3 | Insulin Efsitora Alfa | Type 2 Diabetes | Completed | 2024-05-15past | 1 | |
| Phase 3 | Orforglipron | Diabetes Mellitus, Type 2+19 more | Active, not recruiting | 2027-05 | 3 | |
| Phase 3 | Tirzepatide | Obesity+4 more | Recruiting | 2027-10 | 4 | |
| Phase 3 | Donanemab | Alzheimer Disease+2 more | Active, not recruiting | 2027-11 | 2 | |
| Phase 3 | Lebrikizumab | Atopic Dermatitis+1 more | Enrolling | 2027-12 | 1 | |
| Phase 3 | Duloxetine | Urinary Stress Incontinence | Completed | — | 1 | |
| Phase 2 | Solanezumab | Alzheimer's Disease | Completed | 2009-07past | 1 | |
| Phase 1 | Pemetrexed - Phase 1 | Ovarian Cancer+1 more | Completed | 2010-02past | 1 | |
| Phase 2 | LY2599506 | Diabetes Mellitus, Type 2 | Terminated | 2010-06past | 1 | |
| Phase 2 | Placebo | Migraine Headache | Terminated | 2012-04past | 1 | |
| Phase 1 | LY2886721 | Alzheimer's Disease | Terminated | 2013-08past | 1 | |
| Phase 2 | Testosterone Solution 2% | Ejaculatory Dysfunction+1 more | Completed | 2013-12past | 1 | |
| Phase 1 | LY2157299 | Glioma | Completed | 2015-08past | 1 | |
| Phase 2 | Galcanezumab | Migraine Headache | Completed | 2015-08-19past | 1 | |
| Phase 2 | Lasmiditan | Migraine | Completed | 2017-06-08past | 2 | |
| Phase 2 | Bimagrumab | Obesity+1 more | Active, not recruiting | 2026-01-16past | 1 | |
| Phase 2 | LY4395089 | Crohn Disease | Recruiting | 2027-06 | 1 | |
| Phase 2 | Gemcitabine | Bladder Neoplasms | Completed | — | 1 | |
| Phase 2 | ALIMTA | Carcinoma, Non-Small-Cell Lung | Completed | — | 1 | |
| Phase 1 | IC83/LY2603618 | Cancer | Completed | 2010-03past | 1 | |
| Phase 1 | Tolbutamide | Lymphoma+1 more | Terminated | 2010-12past | 1 | |
| Phase 1 | LY2140023 | Healthy Subjects | Completed | 2011-10past | 1 | |
| Phase 1 | LY2189265 | Diabetes Mellitus, Type 2 | Completed | 2011-11past | 1 | |
| Phase 1 | Ramucirumab (IMC-1121B) | Colorectal Carcinoma | Completed | 2012-02past | 1 | |
| Phase 1 | LY2409021 | Diabetes Mellitus, Type 2 | Completed | 2012-03past | 1 | |
| Phase 1 | LY2228820 | Advanced Cancer | Completed | 2013-02past | 1 | |
| Phase 1 | Evacetrapib | Healthy Volunteers | Completed | 2013-06past | 1 | |
| Phase 1 | LY3045697 | Healthy Volunteers | Completed | 2013-07past | 1 | |
| Phase 1 | Abemaciclib | Neoplasm+2 more | Completed | 2015-08past | 2 | |
| Phase 1 | [¹⁴C]-LY3023414 | Healthy | Completed | 2015-11past | 1 | |
| Phase 1 | LY3002813-IV | Alzheimer Disease | Completed | 2016-08-24past | 1 | |
| Phase 1 | Dulaglutide (Reference) | Healthy | Completed | 2018-06-06past | 1 | |
| Phase 1 | Ramucirumab - IV | Healthy | Completed | 2021-05-09past | 1 | |
| Phase 1 | LY3561774 | Dyslipidemias | Completed | 2022-05-17past | 1 | |
| Phase 1 | Imlunestrant | Healthy | Completed | 2022-11-02past | 1 | |
| Phase 1 | LY3361237 | Psoriasis | Completed | 2022-11-29past | 1 | |
| Phase 1 | LY3502970 | Healthy+1 more | Completed | 2023-09-14past | 1 | |
| Phase 1 | Rosuvastatin | Healthy | Completed | 2023-10-31past | 1 | |
| Phase 1 | LY3841136 | Obesity+1 more | Completed | 2024-01-25past | 1 | |
| Phase 1 | LY3873862 | Healthy | Completed | 2025-04-29past | 1 | |
| Phase 1 | LY3839840 | Healthy | Completed | 2025-05-22past | 1 | |
| Phase 1 | LY4268989 | Healthy | Completed | 2026-02-17past | 1 | |
| Phase 1 | Intramuscular Olanzapine Depot | Schizophrenia+1 more | Completed | — | 1 | |
| N/A | Treatment for Fibromyalgia | Fibromyalgia | Completed | 2011-04past | 1 | |
| N/A | Somatropin (rDNA origin) | Hypopituitarism+2 more | Completed | 2012-12past | 1 | |
| N/A | Retatrutide | n/a | Available | — | 1 |
Valuation
Risk-adjusted NPV
Loading pipeline…
Peer comparison
Cohort check
No peer cohort defined for LLY. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.